

International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 64

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–101) and Recommended (1–62) International Nonproprietary Names can be found in *Cumulative List No. 13, 2009* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 64

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–101) et recommandées (1–62) dans la *Liste récapitulative No. 13, 2009* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 64

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Resolución EB115.R4 (EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–101) y Recomendadas (1–62) se encuentran reunidas en *Cumulative List No. 13, 2009* (disponible sólo en CD-ROM).

Latin, English, French, Spanish:

Recommended INN

Chemical name or description; Molecular formula; Graphic formula

DCI Recommandée

Nom chimique ou description; Formule brute; Formule développée

DCI Recomendada

Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada

acidum zibrofusidicum

zibrofusidic acid


(17Z)-16β-(acetyloxy)-24-bromo-3α,11α-dihydroxy-29-norprotosta-17(20),24-dien-21-oic acid

acide zibrofusidique

acide (17Z)-16β-(acétyloxy)-24-bromo-3α,11α-dihydroxy-29-norprotosta-17(20),24-dién-21-oïque

ácido zibrofusídico

ácido (17Z)-16β-(acetiloxi)-24-bromo-3α,11α-dihidroxi-29-norprotosta-17(20),24-dien-21-oico

C₃₁H₄₇BrO₆**afatinibum**

afatinib


(2E)-N-[4-(3-chloro-4-fluoroanilino)-7-[[[(3S)-oxolan-3-yl]oxy]quinoxazolin-6-yl]-4-(dimethylamino)but-2-enamide

afatinib

(2E)-N-[4-(3-chloro-4-fluoroanilino)-7-[[[(3S)-oxolan-3-yl]oxy]quinoxazolin-6-yl]-4-(diméthylamino)but-2-énamide

afatinib

(2E)-N-[4-(3-cloro-4-fluoroanilino)-7-[[[(3S)-oxolan-3-il]oxi]quinoxazolin-6-il]-4-(dimetilamino)but-2-enamida

C₂₄H₂₅ClFN₅O₃

atagabalinum


atagabalin

[(3*S*,4*S*)-1-(aminométhyl)-3,4-diméthylcyclopent-1-yl]acétique

atagabaline

acide [(3*S*,4*S*)-1-(aminométhyl)-3,4-diméthylcyclopent-1-yl]acétique

atagabalina

ácido [(3*S*,4*S*)-1-(aminometil)-3,4-dimetilciclopent-1-il]acéticoC₁₀H₁₉NO₂**barasertibum**


barasertib

2-{ethyl[3-({4-[(5-{2-[(3-fluorophényl)amino]-2-oxoéthyl})-1*H*-pyrazol-3-yl)amino]quinazolin-7-yl}oxy)propyl]amino}ethyl dihydrogen phosphate

barasertib

dihydrogénophosphate de 2-{éthyl[3-({4-[(5-{2-[(3-fluorophényl)amino]-2-oxoéthyl})-1*H*-pyrazol-3-yl)amino]quinazolin-7-yl}oxy)propyl]aminoéthyle

barasertib

dihidrógenofosfato de 2-{etil[3-({4-[(5-{2-[(3-fluorofenil)amino]-2-oxoetil})-1*H*-pirazol-3-il)amino]quinazolin-7-il}oxi)propil]amino}etiloC₂₆H₃₁F N₇O₆P**benralizumabum #**

benralizumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* IL5RA (interleukin 5 receptor subunit alpha, CD125)], humanized monoclonal antibody; gamma1 heavy chain (1-451) [humanized VH (*Homo sapiens*IGHV1-46*01 (78.60%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) - *Homo sapiens*IGHG1*01 (122-451)], (224-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens*IGKV1-39*01 (87.40%) -IGKJ2*01) [6.3.9] (1'-107') - *Homo sapiens*IGKC*01 (108'-214')]; (230-230'':233-233'')-bisdisulfide dimer

benralizumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* IL5RA (sous-unité alpha du récepteur de l'interleukine 5, CD125)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-451) [VH humanisé (*Homo sapiens*IGHV1-46*01 (78.60%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) - *Homo sapiens*IGHG1*01 (122-451)], (224-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens*IGKV1-39*01 (87.40%) -IGKJ2*01) [6.3.9] (1'-107') - *Homo sapiens*IGKC*01 (108'-214')]; dimère (230-230'':233-233'')-bisdisulfure

inmunoglobulina G1-kappa, anti-[*Homo sapiens* ILR5A (subunidad alfa del receptor de la interleukina 5, CD125)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-451) [VH humanizada (*Homo sapiens* IGHV1-46*01 (78.60%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -*Homo sapiens* IGHG1*01 (122-451)], (224-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizada (*Homo sapiens* IGKV1-39*01 (87.40%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214'')]: dímero (230-230''-233-233'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada				
EVQLVDSGAE	VKKPGASVVK	SCKASGYTFT	SYVIHWVRQR	PQGGLAWMGY 50
INPYNDGKGY	NERFKGKVTI	TDSDRSTSTV	MELSSLSRSD	TAVYLCGREG 100
IRYFELGLDGY	WGQGTLTVTS	SASTKPGSVF	PLAPSSKSTK	GTGAALGCLV 150
KDYPPEPLTV	SWNSGLATSG	VHTFPAVLGS	SLGLYSLSVV	TPVSSSLGTV 200
TYICINNNHK	PNTPKDVKKE	PKSCDKVHTC	PPCAPDEGLV	GPSVFLFPFK 250
PKDTLMISRT	PEVTICVVVD	SHEDPEVKTH	VPYDGVVHNH	AKTKFREEQY 300
NTSYRIVSVL	TLVHQDWLNG	KEYKCGKVSN	ALPAPIEKTI	SKAKQGPQRP 350
QSYTVLPSSR	ELTKNQVSLT	CLVKVGFPSD	TAVESWGNSP	PENNYKPTTP 400
VLDSGGSFFL	YSKLTVDKSR	WQGNVPSFCS	VMHEALHNHY	TQKSLSLSPG 450
K				451

Light chain / Chaîne légère / Cadena ligera				
DIQMTQSPSS	LSASVGDVRY	ITCGTSEDDI	NYLNWYQQK	GKAPKLLIYH 50
TSRLSQGSPVS	RFSGSGSGTD	FTLTISSLQP	EDFATYYCQQ	GTYLPYTFGQ 100
GTKVEIKRTV	AAPSVFIFFP	SDEQLKSGTA	SVVCLLNFFY	PREAKVQWKV 150
DNALQSGNSQ	ESVTEQDSKD	STYLSLSTLT	LSKADYEKKH	VYACEVTHQG 200
LSSPVTSKFSN	RGEC			214



Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro				
Intra-H	22-96	148-204	265-325	371-429
	22"-96"	148"-204"	265"-325"	371"-429"
Intra-L	23'-88"	134'-194"		
	23'''-88'''	134'''-194'''		
Inter-H-L	224-214'	224"-214'''		
Inter-H-H	230-230"	233-233"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
301.301"

2,2',2''-[10-(2-[[6-[[5-[(3aS,4S,6aR)-2-oxohexahydro-1*H*-thieno[3,4-*d*]imidazol-4-yl]pentyl]amino)hexyl]amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl]triacetic acid

acide 2,2',2''-[10-(2-{[6-({5-[(3*a*S,4*S*,6*a**R*)-2-oxohexahydro-1*H*-thiéf[3,4-*d*]imidazol-4-yl)pentyl]amino)hexyl]amino}-2-oxoéthyl)-1,4,7,10-tétrazacyclododécane-1,4,7-triyl]triacétique

ácido [10-(2-[[6-[[5-[(3*A*S,4*S*,6*A*R)-2-oxohexahidro-1*H*-tieno[3,4-*d*]imidazol-4-il]pentil]amino)hexil]amino)-2-oxoetil)-1,4,7,10-tetraazaciclododecano-1,4,7-triil]triacético




canagliflozinum
canagliflozin(1*S*)-1,5-anhydro-1-*C*-(3-([5-(4-fluorophenyl)thiophen-2-yl]methyl)-4-methylphenyl)-*D*-glucitol

canagliflozine

(1*S*)-1,5-anhydro-1-*C*-(3-([5-(4-fluorophényl)thiophén-2-yl]méthyl)-4-méthylphényl)-*D*-glucitol


canagliflozina

(1*S*)-1,5-anhidro-1-*C*-(3-([5-(4-fluorofenil)tiófen-2-il]metil)-4-metilfenil)-*D*-glucitol $C_{24}H_{25}FO_5S$ **carotegrastum**
carotegrast(2*S*)-2-(2,6-dichlorobenzamido)-3-{4-[6-(dimethylamino)-1-methyl-2,4-dioxo-1,4-dihydroquinazolin-3(2*H*)-yl]phenyl}propanoic acid

carotégrast

acide (2*S*)-2-(2,6-dichlorobenzamido)-3-{4-[6-(diméthylamino)-1-méthyl-2,4-dioxo-1,4-dihydroquinazolin-3(2*H*)-yl]phényl}propanoïque

carotegrast

ácido (2*S*)-2-(2,6-diclorobenzamido)-3-{4-[6-(dimetilamino)-1-metil-2,4-dioxo-1,4-dihidroquinazolin-3(2*H*)-il]fenil}propanoico $C_{27}H_{24}Cl_2N_4O_5$ 

condoliasum #

condoliase

endolyase, chondroïtine ABC (C-ABC). glycosaminoglycan lyase
chondroïtine ABC endolyase 1 (chondroïtinase ABC) *Proteus vulgaris*

condoliase

endolyase, chondroïtine ABC (C-ABC). glycosaminoglycane lyase
chondroïtine ABC endolyase 1 (chondroïtinase ABC) *Proteus vulgaris*

condoliasa

endoliasa, condroitina ABC (C-ABC). glicosaminoglicano liasa
condroitina ABC endoliasa 1 (condroitinasa ABC) *Proteus vulgaris*

C₅₀₃₉H₇₇₇₀N₁₃₆₀O₁₅₂₅S₂₂

ATSNPAFDPK	NLMQSEIYHF	AQNNPLADFS	SDKNSILTLS	DKRSIMGNQS	50
LLWKWKGGSS	FTLHKKLIVP	TDKEASKAWG	RSSTPVFSFW	LYNEKPIDGY	100
LTIDFGEKLI	STSEAQAGFK	VKLDFTGWRA	VGVSLLNNDLE	NREMTLNATN	150
TSSDGTQDSI	GRSLGAKVDS	IRFKAPSNVS	QGEIYIDRIM	FSVDDARYQW	200
SDYQVKTRLS	EPEIQFHNVK	PQLPVTPENL	AAIDLIRQRL	INEFVGGEKE	250
TNLALEENIS	KLKSDFDALN	IHTLANGGTQ	GRHLITDKQI	IYQPENLNS	300
QDKQLFDNYV	ILGNYTTLMF	NISRAYVLEK	DPTQKAQLKQ	MYLLMTKHL	350
DQGFKVGSAL	VTTHHWGYSS	RWWYISTLLM	SDALKEANLQ	TQVYDSSLWY	400
SREFKSSFDM	KVSADSSDLD	YFNTLSRQHL	ALLLEPDDQ	KRINLVNTFS	450
HYITGALTQV	PPGGKDGRLP	DGTAWRHEGN	YPGYSFPAPK	NASQLIYLLR	500
DTPFSVGESG	WNNLKAMVS	AWIYSNPEVG	LPLAGRHPFN	SPSLKSVAAQ	550
YYWLAMSAKS	SPDKTLASIY	LAI SDKTQNE	STAIFGETIT	PASLPQGFYA	600
FNGGAFGIHR	WQDKMVTLKA	YNTNVWSSEI	YNKDNRYGRY	QSHGVAQIVS	650
NGSQLSQGYM	QEGWDWNRME	GATTIHLPLK	DLDSPKPHLT	MQRGERGFSG	700
TSSLEGQYGM	MAFNLIYPAN	LERFDPNFTA	KKSVLAADNH	LIFIGSNINS	750
SDKNKNVETT	LFQHAITPTL	NTLWINGQKI	ENMPYQTTLQ	QGDWLDISNG	800
NGYLITQAEK	VNVSROHQVS	AENKNRQFTE	GNFSSAWIDH	STRPKDASYE	850
YMFVLDATPE	KMGEMAQKFR	ENNGLYQVLR	KDKDVHIILD	KLSNVTGYAF	900
YQPASIEDKW	IKKVNKPAIV	MTHRQKDTLI	VSAVTPDLNM	TRQKAATPVT	950
INVTINGKWQ	SADKNSEVKY	QVSGDNTELT	FTSYFGIPQE	IKLSPLP	997

dalotuzumabum #

dalotuzumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* IGF1R (insulin-like growth factor 1 receptor, IGF1-R, IGF-1R, CD221)], humanized monoclonal antibody;

gamma1 heavy chain (1-447) [humanized VH (*Homo sapiens*IGHV4-61*08 (79.80%) -(IGHD)-IGHJ4*01) [9.7.10] (1-117) -*Homo sapiens*IGHG1*03 (118-447)], (220-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens*IGKV2-29*02 (78.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens*IGKC*01 (113'-219')]; (226-226'':229-229'')-bisdisulfide dimer

dalotuzumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* IGF1R (récepteur du facteur de croissance 1 analogue à l'insuline (IGF1-R, IGF-1R, CD221)], anticorps monoclonal humanisé;

chaîne lourde gamma1 (1-447) [VH humanisé (*Homo sapiens*IGHV4-61*08 (79.80%) -(IGHD)-IGHJ4*01) [9.7.10] (1-117) -*Homo sapiens*IGHG1*03 (118-447)], (220-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens*IGKV2-29*02 (78.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens*IGKC*01 (113'-219')]; dimère (226-226'':229-229'')-bisdisulfure

dalotuzumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* IGF1R (receptor del factor de crecimiento similar a la insulina 1(IGF1-R, IGF-1R, CD221)], anticuerpo monoclonal humanizado;

cadena pesada gamma1 (1-447) [VH humanizada (*Homo sapiens*IGHV4-61*08 (79.80%) -(IGHD)-IGHJ4*01) [9.7.10] (1-117) -*Homo sapiens*IGHG1*03 (118-447)], (220-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizada (*Homo sapiens*IGKV2-29*02 (78.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens*IGKC*01 (113'-219')]; dímero (226-226'':229-229'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLQQSGPG LVKPSQTLST TCTVSGWSIS GGWLWNWIRQ PPGKGLQWIG 50
 WISWDGTTNNW KPSLKDRTVI SVDTSKNQFS LKLSSVTAAAD TAVWWCARWG 100
 RVFFDWWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
 PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
 NVNHKPSNTK VDKRVEPKSC DKHTTCPPCP APELLGGPSV FLFPPKPKDT 250
 LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
 RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350
 LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTTPVLDL 400
 DGSFFLYSKL TVDKSRWQQG NVFSCSVME ALHNHYTQKS LSLSPGK 447

Light chain / Chaîne légère / Cadena ligera

DIVMTQSPLS LPVTPGQFAS ISCRSSQSIV HSNNGTTLQW WLQKPGQSPQ 50
 LLIWKVSNRL WGVPDFRFGS GSGTDFTLKI SRVQAQDVGV WWCFFGSHVP 100
 WTFGQGTQVQ IKRTVAAPSV FIFPPSDEQL KSGTASVCL LNNFYPREAK 150
 VQWKVDNALQ SGNSQESVTE QDSKSTYSL SSTLTLSKAD YEKHKVYACE 200
 VTHQGLSSPV TKSFNREGC 219

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 144-200 261-321 367-425
 22"-96" 144"-200" 261"-321" 367"-425"
 Intra-L 23'-93' 139'-199'
 23'''-93''' 139'''-199'''
 Inter-H-L 220-219' 220"-219"
 Inter-H-H 226-226" 229-229"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

297, 297"

danoprevirum

danoprevir

(2*R*,6*S*,12*Z*,13*aS*,14*aR*,16*aS*)-6-[(*tert*-butoxycarbonyl)amino]-
 14*a*-[*N*-(cyclopropanesulfonyl)carbamoyl]-5,16-dioxo-
 1,2,3,5,6,7,8,9,10,11,13*a*,14,14*a*,15,16,16*a*-
 hexadecahydrocyclopropa[e]pyrrolo[1,2-*a*][1,4]diazacyclopentadecin-
 2-yl 4-fluoro-1,3-dihydro-2*H*-isoindole-2-carboxylate


danoprévir

4-fluoro-1,3-dihydro-2*H*-isoindole-2-carboxylate de
 (2*R*,6*S*,12*Z*,13*aS*,14*aR*,16*aS*)-6-[(*tert*-butoxycarbonyl)amino]-
 14*a*-[*N*-(cyclopropanesulfonyl)carbamoyl]-5,16-dioxo-
 1,2,3,5,6,7,8,9,10,11,13*a*,14,14*a*,15,16,16*a*-
 hexadécahydrocyclopropa[e]pyrrolo[1,2-*a*][1,4]diazacyclopentadécin-
 2-yle

danoprevir

4-fluoro-1,3-dihydro-2*H*-isoindol-2-carboxilato de
 (2*R*,6*S*,12*Z*,13*aS*,14*aR*,16*aS*)-6-[(*terc*-butoxicarbonil)amino]-
 14*a*-[*N*-(ciclopropanosulfonil)carbamoil]-5,16-dioxo-
 1,2,3,5,6,7,8,9,10,11,13*a*,14,14*a*,15,16,16*a*-
 hexadecahidrociclopropa[e]pirrolo[1,2-*a*][1,4]diazacyclopentadecin-
 2-ilo

C₃₅H₄₆FN₅O₉S



derenofyllinum


derenofylline

trans-4-[(2-phenyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)amino]cyclohexanol

dérénofylline

trans-4-[(2-phényl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)amino]cyclohexanol

derenofilina

trans-4-[(2-fenil-7*H*-pirrolo[2,3-*d*]pirimidin-4-il)amino]ciclohexanolC₁₈H₂₀N₄O**dilmapimodum**


dilmapimod

8-(2,6-difluorophenyl)-2-[(1,3-dihydroxypropan-2-yl)amino]-4-(4-fluoro-2-methylphenyl)pyrido[2,3-*d*]pyrimidin-7(8*H*)-one

dilmapimod

8-(2,6-difluorophényl)-2-[(1,3-dihydroxypropan-2-yl)amino]-4-(4-fluoro-2-méthylphényl)pyrido[2,3-*d*]pyrimidin-7(8*H*)-one

dilmapimod

8-(2,6-difluorofenil)-2-[(1,3-dihidroxiopropan-2-il)amino]-4-(4-fluoro-2-metilfenil)pirido[2,3-*d*]pirimidin-7(8*H*)-onaC₂₃H₁₉F₃N₄O₃**dinaciclibum**

dinaciclib



3-[(3-ethyl-5-[(2*S*)-2-(2-hydroxyethyl)piperidin-1-yl]pyrazolo[1,5-*a*]pyrimidin-7-yl)amino)methyl]pyridine 1-oxide

dinaciclib

1-oxyde de 3-[(3-éthyl-5-[(2*S*)-2-(2-hydroxyéthyl)pipéridin-1-yl]pyrazolo[1,5-*a*]pyrimidin-7-yl)amino)méthyl]pyridine

dinaciclib

1-óxido de 3-[(3-etil-5-[(2*S*)-2-(2-hidroxietyl)piperidin-1-il]pirazolo[1,5-*a*]pirimidin-7-il)amino)metil]piridina

**dipraglurantum**



dipraglurant

6-fluoro-2-[4-(pyridin-2-yl)but-3-yn-1-yl]imidazo[1,2-*a*]pyridine

dipraglurant

6-fluoro-2-[4-(pyridin-2-yl)but-3-yn-1-yl]imidazo[1,2-*a*]pyridine

dipraglurant

6-fluoro-2-[4-(piridin-2-il)but-3-in-1-il]imidazo[1,2-*a*]piridina**duvoglustatum**



duvoglustat

(2*R*,3*R*,4*R*,5*S*)-2-(hydroxymethyl)piperidine-3,4,5-triol

duvoglustat

(2*R*,3*R*,4*R*,5*S*)-2-(hydroxyméthyl)pipéridine-3,4,5-triol

duvoglustat

(2*R*,3*R*,4*R*,5*S*)-2-(hidroximetil)piperidina-3,4,5-triol**efatutazonum**

efatutazone



rac-5-[(4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1*H*-benzimidazol-2-yl]methoxy]phenyl)methyl]-1,3-thiazolidine-2,4-dione

éfatutazone

rac-5-[(4-[[6-(4-amino-3,5-diméthylphénoxy)-1-méthyl-1*H*-benzimidazol-2-yl]méthoxy]phényl)méthyl]thiazolidine-2,4-dione

efatutazona

rac-5-[(4-[[6-(4-amino-3,5-dimetilfenoxi)-1-metil-1*H*-benzoimidazol-2-il]metoxi]fenil)metil]-1,3-tiazolidina-2,4-diona



and enantiomer
et énantiomère
y enantiómero

emicerfontum

emicerfont



1-{1-[1-(4-methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1*H*-pyrrolo[2,3-*b*]pyridin-4-yl]-1*H*-pyrazol-3-yl}imidazolidin-2-one

emicerfont

1-{1-[1-(4-méthoxy-2-méthylphényl)-6-méthyl-2,3-dihydro-1*H*-pyrrolo[2,3-*b*]pyridin-4-yl]-1*H*-pyrazol-3-yl}imidazolidin-2-one

emicerfont

1-{1-[1-(4-metoxi-2-metilfenil)-6-metil-2,3-dihidro-1*H*-pirrolo[2,3-*b*]piridin-4-il]-1*H*-pirazol-3-il}imidazolidin-2-ona


florbetabenum (¹⁸F)

 florbetaben (¹⁸F)



4-((1*E*)-2-(4-{2-[2-(2-[¹⁸F]fluoroethoxy)ethoxy]ethoxy}phenyl)eth-1-en-1-yl)-*N*-methylaniline

 florbétabène (¹⁸F)

4-((1*E*)-2-(4-{2-[2-(2-[¹⁸F]fluoroéthoxy)éthoxy]éthoxy}phényl)éth-1-én-1-yl)-*N*-méthylaniline

 florbetabén (¹⁸F)

4-((1*E*)-2-(4-{2-[2-(2-[¹⁸F]fluoroetoxi)etoxi]etoxi}fenil)et-1-en-1-il)-*N*-metilanilina



foretinibum

foretinib


N-[3-fluoro-4-({6-methoxy-7-[3-(morpholin-4-yl)propoxy]quinolin-4-yl}oxy)phenyl]-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

forétinib

N-[3-fluoro-4-({6-méthoxy-7-[3-(morpholin-4-yl)propoxy]quinoléin-4-yl}oxy)phényl]-*N'*-(4-fluorophényl)cyclopropane-1,1-dicarboxamide

foretinib

N-[3-fluoro-4-({6-metoxi-7-[3-(morfolin-4-il)propoxi]quinolin-4-il}oxi)fenil]-*N'*-(4-fluorofenil)ciclopropano-1,1-dicarboxamida

C₃₄H₃₄F₂N₄O₆**glembatumumabum #**

glembatumumab

immunoglobulin G2-kappa, anti-[*Homo sapiens* GPNMB (glycoprotein transmembrane NMB, hematopoietic growth factor inducible neurokinin-1 type, HGFIN) extracellular domain], *Homo sapiens* monoclonal antibody; gamma2 heavy chain (1-445) [*Homo sapiens* VH (IGHV4-31*02 (94.90%) -(IGHD)-IGHJ4*01) [10.7.11] (1-119) -IGHG2*01 (120-445)], (133-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-15*01 (96.80%) -IGKJ1*01) [6.3.10] (1'-108') -IGKC*01 (109'-215')]; (221-221'':222-222'':225-225'':228-228'')-tetrakisdisulfide dimer

glembatumumab

immunoglobuline G2-kappa, anti-[*Homo sapiens* GPNMB (glycoprotéine transmembranaire NMB, facteur de croissance hématopoïétique inductible type neurokinine-1, HGFIN) domaine extracellulaire], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma2 (1-445) [*Homo sapiens* VH (IGHV4-31*02 (94.90%) -(IGHD)-IGHJ4*01) [10.7.11] (1-119) -IGHG2*01 (120-445)], (133-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-15*01 (96.80%) -IGKJ1*01) [6.3.10] (1'-108') -IGKC*01 (109'-215')]; dimère (221-221'':222-222'':225-225'':228-228'')-tétrakisdisulfure

glembatumumab

inmunoglobulina G2-kappa, anti-[*Homo sapiens* GPNMB (glicoproteína transmembranosa NMB, factor de crecimiento hematopoyético inductible tipo neuroquinina-1, HGFIN) dominio extracelular], *Homo sapiens* anticuerpo monoclonal; cadena pesada gamma2 (1-445) [*Homo sapiens* VH (IGHV4-31*02 (94.90%) -(IGHD)-IGHJ4*01) [10.7.11] (1-119) -IGHG2*01 (120-445)], (133-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-15*01 (96.80%) -IGKJ1*01) [6.3.10] (1'-108') -IGKC*01 (109'-215')]; dímero (221-221'':222-222'':225-225'':228-228'')-tetraakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLQESGPG	LVKPSQTL	SL	TCTVSGGS	IS	SFNYYWSWIR	HHPGKGLEWI	50
GYIYYSGSTY	SNPSLKSRVT	ISVDTSKNQF	SLTLSSVTAA	DTAVVYCARG			100
YNWNYFDYWG	QGTLLVTSSA	STKGPSVFPL	APCSRSTSES	TAALGCLVKD			150
YFPEPVTVSW	NSGALTSGVH	TTPAVLQSSG	LYSLSSVTV	PSSNFGTQTY			200
TCNVDHKPSN	TKVDKTVK	CCVECPPCPA	PPVAGPSVFL	FPPKPKDTLM			250
ISRTPVETCV	VVDVSHEDPE	VQFNWYVDGV	EVHNAKTKPR	EEQFNSTFRV			300
VSVLTVVHQD	WLNKEYKCK	VSNKGLPAPI	EKTISKTKGQ	PREPQVYTL			350
PSREEMTKNQ	VSLTCLVKG	F	YPSDIAVEWE	SNGQPENNYK	TTPPMLDSDG		400
SFFLYSKLTV	DKSRWQQGNV	F	SCSVMEAL	HNHYTQKSLS	LSPGK		445

Light chain / Chaîne légère / Cadena ligera

EIVMTQSPAT	LSVSPGERAT	L	SCRASQSD	NNLVWYQQK	GPAPRLLIYG		50
ASTRATGIPA	RFGSGSGSTE	FTLTIS	SLQS	EDFAVYICQ	YNNWPPWTFG		100
QGTVKVEIKRT	VAAFSVFIFP	PSDEQLKSGT	ASVVCLLNNF	YPREAKVQWK			150
VDNALQSGNS	QESVTEQDSK	D	STYSLSTL	TL	SKADYEKH	KVYACEVTHQ	200
GLSSPVTKSF	NRGEC						215

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H	22-97	146-202	259-319	365-423
	22"-97"	146"-202"	259"-319"	365"-423"
Intra-L	23'-88'	135'-195'		
	23'''-88'''	135'''-195'''		
Inter-H-L	133-215'	133"-215"		
Inter-H-H	221-221"	222-222"	225-225"	228-228"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
295, 295"

guaraprolosum
guaraprolose

(1→6)-α-D-galactopyrano-(1→4)-β-D-mannopyranan
2-hydroxypropyl ether


guaraprolose

éther 2-hydroxypropylique du (1→6)-α-D-galactopyrano-
(1→4)-β-D-mannopyranane

guaraprolosa

éter 2-hidroxiopropílico de (1→6)-α-D-galactopirano-
(1→4)-β-D-mannopirano

$[C_{18}H_{30}O_{15} (C_3H_6O)_x]_n$



R = H, CH₂-CHOH-CH₃

lasmiditanum
lasmiditan



2,4,6-trifluoro-N-{6-[(1-methylpiperidine-4-yl)carbonyl]pyridin-
2-yl}benzamide

lasmiditan

2,4,6-trifluoro-N-{6-[(1-méthylpipéridine-4-yl)carbonyl]pyridin-
2-yl}benzamide

lasmiditán

2,4,6-trifluoro-N-{6-[(1-metilpiperidina-4-il)carbonil]piridin-
2-il}benzamida

**latrepirdinum**


latrepirdine

2,8-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-2,3,4,5-tetrahydro-1*H*-pyrido[4,3-*b*]indole

latrépirdine

2,8-diméthyl-5-[2-(6-méthylpyridin-3-yl)éthyl]-2,3,4,5-tétrahydro-1*H*-pyrido[4,3-*b*]indole

latrepirdina

2,8-dimetil-5-[2-(6-metilpiridin-3-il)etil]-2,3,4,5-tetrahydro-1*H*-pirido[4,3-*b*]indol**linifanibum**



linifanib

1-[4-(3-amino-1*H*-indazol-4-yl)phenyl]-3-(2-fluoro-5-methylphenyl)urea

linifanib

1-[4-(3-amino-1*H*-indazol-4-yl)phényl]-3-(2-fluoro-5-méthylphényl)urée

linifanib

1-[4-(3-amino-1*H*-indazol-4-il)fenil]-3-(2-fluoro-5-metilfenil)urea**lunacalcipolum**

lunacalcipol



(1*S*,3*R*,5*Z*,7*E*,23*E*)-24-(2-methylpropane-2-sulfonyl)-9,10-secochola-5,7,10(19),16,23-pentaene-1,3-diol

lunacalcipol

(1*S*,3*R*,5*Z*,7*E*,23*E*)-24-(2-méthylpropane-2-sulfonyl)-9,10-sécochola-5,7,10(19),16,23-pentaène-1,3-diol

lunacalcipol

(1*S*,3*R*,5*Z*,7*E*,23*E*)-24-(2-metilpropano-2-sulfonil)-9,10-secocola-5,7,10(19),16,23-pentaeno-1,3-diol

**mapracoratum**

mapracorat



(2*R*)-1,1,1-trifluoro-4-(5-fluoro-2,3-dihydro-1-benzofuran-7-yl)-4-methyl-2-[[[(2-methylquinolin-5-yl)amino]methyl]pentan-2-ol

mapracorat

(2*R*)-1,1,1-trifluoro-4-(5-fluoro-2,3-dihydro-1-benzofuran-7-yl)-4-méthyl-2-[[[(2-méthylquinoléin-5-yl)amino]méthyl]pentan-2-ol

mapracorat

(2*R*)-1,1,1-trifluoro-4-(5-fluoro-2,3-dihidro-1-benzofuran-7-il)-4-metil-2-[[[(2-metilquinolin-5-il)amino]metil]pentan-2-ol

**marizomibum**

marizomib



(1*R*,4*R*,5*S*)-4-(2-chloroethyl)-1-[(*S*)-[(1*S*)-cyclohex-2-en-1-yl](hydroxymethyl)-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione

marizomib

(1*R*,4*R*,5*S*)-4-(2-chloroéthyl)-1-[(*S*)-[(1*S*)-cyclohex-2-én-1-yl](hydroxyméthyl)-5-méthyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione

marizomib

(1*R*,4*R*,5*S*)-4-(2-cloroetil)-1-[(*S*)-[(1*S*)-ciclohex-2-en-1-il](hidroxi)metil]-5-metil-6-oxa-2-azabicyclo[3.2.0]heptano-3,7-diona



mavrilimumabum #

mavrilimumab

immunoglobulin G4-lambda, anti-[*Homo sapiens* CSF2RA (granulocyte-macrophage colony-stimulating factor subunit alpha, GM-CSF-R-alpha, CD116)], *Homo sapiens* monoclonal antibody;

gamma4 heavy chain (1-447) [*Homo sapiens* VH (IGHV1-24*01 (93.80%) -(IGHD)-IGHJ3*02) [8.8.13] (1-120) -IGHG4*01 (121-447)], (134-216')-disulfide with lambda light chain (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-40*01 (87.90%) -IGLJ2*01) [9.3.11] (1'-111') - IGLC2*01 (112'-217'')]; (226-226":229-229")-bisdisulfide dimer

mavrilimumab

immunoglobuline G4-lambda, anti-[*Homo sapiens* CSF2RA (sous-unité alpha du récepteur du facteur stimulant les colonies de granulocytes et de macrophages, GM-CSF-R-alpha, CD116)], *Homo sapiens* anticorps monoclonal;

chaîne lourde gamma4 (1-447) [*Homo sapiens* VH (IGHV1-24*01 (93.80%) -(IGHD)-IGHJ3*02) [8.8.13] (1-120) -IGHG4*01 (121-447)], (134-216')-disulfure avec la chaîne légère lambda (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-40*01 (87.90%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217'')]; dimère (226-226":229-229")-bisdisulfure

mavrilimumab

inmunoglobulina G4-lambda, anti-[CSF2RA (subunidad alfa del receptor del factor estimulante de colonias de granulocitos y macrófagos, GM-CSF-R-alfa, CD116) de *Homo sapiens*], anticuerpo monoclonal de *Homo sapiens*; cadena pesada gamma4 (1-447) [*Homo sapiens* VH (IGHV1-24*01 (93.80%) -(IGHD)-IGHJ3*02) [8.8.13] (1-120) -IGHG4*01 (121-447)], (134-216')-disulfuro con la cadena ligera lambda (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-40*01 (87.90%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217'')]; dímero (226-226":229-229")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE	VKKPGASVKV	SCRVSQYTLT	ELSIHWVRQA	PGKGLEWMGG	50
FDPEENEIVY	AQRFQGRVTM	TEDTSTDYAY	MELSSLRSED	TAVYYCAIVG	100
SFSPLTLGLW	GQGTMTVTVS	ASTKGPSVFP	LAPCSRSTSE	STAALGCLVK	150
DYFPEPVTVS	WNSGALTSGV	HTFPAVLQSS	GLYSLSSVVT	VPSSSLGTKT	200
YTCNVDHKPS	NTKVDKRVES	KYGPPCPSCP	APEFLGGPSV	FLFPPPKPKDT	250
LMISRTPEVT	CVVVDVSQED	PEVQFNWYVD	GVEVHNAKTK	PREEQFNSTY	300
RVVSVLTVLH	QDWLNGKEYK	CKVSNKGLPS	SIEKTISKAK	GQPREPQVYT	350
LPFSQEEMTK	NQVSLTCLVK	GFYPDSIAVE	WESNGQPENN	YKTTTPPVLD	400
DGSFFLYSRL	TVDKSRWQEG	NVFSQCSVMHE	ALHNHYTQKS	LSLSLGK	447

Light chain / Chaîne légère / Cadena ligera

QSVLTQPPSV	SGAPGQRVTI	SCTGSGSNIG	APYDVSWYQQ	LPGTAPKLLI	50
YHNNKRPSPV	PDRFSGSKSG	TSASLAITGL	QAEDEADYYC	ATVEAGLSGS	100
VFGGGTKLTV	LGQPKAAPSV	TLFPPSSEEL	QANKATLVCL	ISDFYPGAVT	150
VAWKADSSPV	KAGVETTTPS	KQSNNKYAAS	SYLSLTPEQW	KSHRSYSCQV	200
THEGSTVEKT	VAPTECS				217

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H	22-96	147-203	261-321	367-425
	22"-96"	147"-203"	261"-321"	367"-425"
Intra-L	22'-90'	139'-198'		
	22'''-90'''	139'''-198'''		
Inter-H-L	134-216'	134"-216"		
Inter-H-H	226-226"	229-229"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

297, 297"

moxetumomabum pasudotoxum #
moxetumomab pasudotox

immunoglobulin Fv fragment fused to *Pseudomonas* toxin, anti-[*Homo sapiens* CD22 (sialic acid-binding Ig-like lectin 2, Siglec-2, SIGLEC2, Leu-14, B-lymphocyte cell adhesion molecule, BL-CAM)], *Mus musculus* monoclonal antibody disulfide stabilized Fv fragment with the variable heavy VH domain fused with the truncated form PE38 of *Pseudomonas aeruginosa* exotoxin A (VH-PE38), disulfide linked with the variable kappa domain (V-KAPPA)]; VH-PE38 (1-476) comprising the VH domain (1-123) [methionyl -*Mus musculus* VH [(IGHV5-12-1*01 -(IGHD)-IGHJ3*01) [8.8.16] (2-123)] fused with a 7-mer linker (124-130) and with the *Pseudomonas aeruginosa* exotoxin A (ETA) PE38 fragment (131-476) [277-638 precursor fragment with del 389-405>N (131-476), containing domain II (131-243) with furin proteolytic cleavage site (152-164), domain Ib (244-267), domain III (268-476)], (45-101')-disulfide with V-KAPPA (1'-108') [methionyl -*Mus musculus* V-KAPPA [(IGHKV10-96*01 -IGKJ1*01) [6.3.9] (2'-108')]

moxétumomab pasudotox

fragment Fv d'immunoglobuline fusionné à la toxine de *Pseudomonas*, anti-[*Homo sapiens* CD22 (Ig-like lectine 2 liant l'acide sialique, Siglec-2, SIGLEC2, Leu-14, molécule d'adhésion cellulaire du lymphocyte B, BL-CAM)], *Mus musculus* fragment Fv d'anticorps monoclonal stabilisé par un pont disulfure avec le domaine VH de la chaîne lourde fusionné à la forme tronquée PE38 de l'exotoxine A de *Pseudomonas aeruginosa* (VH-PE38), lié par un pont disulfure au domaine variable kappa (V-KAPPA)]; VH-PE38 (1-476) comprenant le domaine VH (1-123) [méthionyl -*Mus musculus* VH [(IGHV5-12-1*01 -(IGHD)-IGHJ3*01) [8.8.16] (2-123)] fusionné à un 7-mer linker (124-130) et au fragment PE38 de l'exotoxine A de *Pseudomonas aeruginosa* (ETA) (131-476) [fragment précurseur 277-638 avec del 389-405>N (131-476), comprenant domaine II (131-243) dont le site de clivage protéolytique par la furine (152-164), domaine Ib (244-267), domaine III (268-476)], (45-101')- disulfure avec V-KAPPA (1'-108') [méthionyl- *Mus musculus* V-KAPPA (IGHKV10-96*01 -IGKJ1*01) [6.3.9] (2'-108')]

moxetumomab pasudotox

fragmento Fv de inmunoglobulina fusionado con toxina de *Pseudomonas*, anti-[*Homo sapiens* CD22 (lectina de tipo inmunoglobulina 2 que se une al ácido siálico, Siglec-2, SIGLEC2, Leu-14, molécula de adhesión celular del linfocito B, BL-CAM)], *Mus musculus* fragmento Fv de anticuerpo monoclonal estabilizado por un puente disulfuro con el dominio VH de la cadena pesada fusionado a la forma truncada PE38 de la exotoxina A de *Pseudomonas aeruginosa* (VH-PE38), unida por un puente disulfuro al dominio variable kappa (V-KAPPA)]; VH-PE38 (1-476) que comprende el dominio VH (1-123) [metionil -*Mus musculus* VH [(IGHV5-12-1*01 -(IGHD)-IGHJ3*01) [8.8.16] (2-123)] fusionado a un heptámero de unión(124-130) y al fragmento PE38 de la exotoxina A de *Pseudomonas aeruginosa* (ETA) (131-476) [fragmento precursor 277-638 con del 389-405>N (131-476), comprende el dominio II (131-243) con el sitio de ruptura proteolítica por la furina (152-164), dominio Ib (244-267), dominio III (268-476)], (45-101')- disulfuro con V-KAPPA (1'-108') [metionil- *Mus musculus* V-KAPPA (IGHKV10-96*01 -IGKJ1*01) [6.3.9] (2'-108')]

VH-PE38 chain / Chaîne VH-PE38 / Cadena VH-PE38
 MEVQLVESGG GLVKPGGSLK LSCAASGFAP SIYDMSWVRQ TPEKCLEWVA 50
 YISSGGGTTY YPDTVKGRFT ISRDNKNTL YLQMSCLKSE DTAMYCARH 100
 SGYGTHTWGL FAYWQGQTLV TVSAKASGGP EGGSLAALTA HQACHLPLET 150
 FTRHRQPRGW EQLEQCGYPV QRLVALYLAA RLSWNQVDQV IRNALASPGS 200
 GGDLEAIRE QPEQARLALT LAAAESERFV RQGTGNDEAG AANGPADSGD 250
 ALLERNYPTG AEFLGDGGDV SFSTRGTQNW TVERLLQAGR QLEERGYPV 300
 GYHGTFLCAA QSIYFGGVRA RSQDLDAIWR GFYIAGDPAL AYGYAQDQEP 350
 DARGIRNGA LLRVYVPRSS LPGAFTSLT LAAPEAAGEV ERLIGHPLPL 400
 RLDAITGPEE EGGRLTILG WPLAERTVVI PSAIPTDPRN VGGDLDPSSI 450
 PDKEQAISAL PDYASQPGKP PREDLK 476

V-KAPPA chain / Chaîne V-KAPPA / Cadena V-KAPPA
 MDIQMTQTTS SLSASLGDRV TISCRAQDI SNYLNWYQQK PDGTVKLLIY 50
 YTSILHSGVP SRFSGSGSGT DYSLTISNLE QEDFATYFCQ QGNTLPWTFG 100
 CGTKLEIK 108

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 Intra-H 23-97 144-166
 Intra-L 24'-89'
 Inter-H-L 45-101'

narlaprevirum
 narlaprevir

(1*R*,2*S*,5*S*)-*N*-[(3*S*)-1-(cyclopropylamino)-1,2-dioxoheptan-3-yl]-3-[(2*S*)-3,3-dimethyl-2-[(1-[(2-methylpropane-2-sulfonyl)methyl]cyclohexyl)carbamoyl]amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide


narlaprévir

(1*R*,2*S*,5*S*)-*N*-[(3*S*)-1-(cyclopropylamino)-1,2-dioxoheptan-3-yl]-3-[(2*S*)-3,3-diméthyl-2-[(1-[(2-méthylpropane-2-sulfonyl)méthyl]cyclohexyl)carbamoyl]amino]butanoyl]-6,6-diméthyl-3-azabicyclo[3.1.0]hexane-2-carboxamide

narlaprevir

(1*R*,2*S*,5*S*)-*N*-[(3*S*)-1-(ciclopropilamino)-1,2-dioxoheptan-3-yl]-3-[(2*S*)-3,3-dimetil-2-[(1-[(2-metilpropane-2-sulfonyl)metil]ciclohexil)carbamoyl]amino]butanoyl]-6,6-dimetil-3-azabicyclo[3.1.0]hexane-2-carboxamida

C₃₆H₆₁N₅O₇S



omadacyclinum
 omadacycline


(4*S*,4*aS*,5*aR*,12*aS*)-4,7-bis(dimethylamino)-9-[(2,2-dimethylpropyl)amino]methyl]-3,10,12,12*a*-tetrahydroxy-1,11-dioxo-1,4,4*a*,5,5*a*,6,11,12*a*-octahydrotetracene-2-carboxamide

omadacycline

(4*S*,4*aS*,5*aR*,12*aS*)-4,7-bis(diméthylamino)-9-[(2,2-diméthylpropyl)amino]méthyl]-3,10,12,12*a*-tétrahydroxy-1,11-dioxo-1,4,4*a*,5,5*a*,6,11,12*a*-octahydrotétracène-2-carboxamide

omadaciclina

(4*S*,4*aS*,5*aR*,12*aS*)-4,7-bis(dimetilamino)-9-[(2,2-dimetilpropil)amino]metil]-3,10,12,12*a*-tetrahidroxi-1,11-dioxo-1,4,4*a*,5,5*a*,6,11,12*a*-octahidrotetraceno-2-carboxamida

$C_{29}H_{40}N_4O_7$ **omecantivum mecarbilum**

omecantiv mecarbil


methyl 4-[(2-fluoro-3-[[N-(6-methylpyridin-3-yl)carbamoyl]amino]phenyl)methyl]piperazine-1-carboxylate

omécantiv mécarbil

4-[(2-fluoro-3-[[N-(6-méthylpyridin-3-yl)carbamoyl]amino]phényl)méthyl]pipérazine-1-carboxylate de méthyle

omecantiv mecarbilo

4-[(2-fluoro-3-[[N-(6-metilpiridin-3-il)carbamoi]amino]fenil)metil]piperazina-1-carboxilato de metilo

 $C_{20}H_{24}FN_5O_3$ **plinabulinum**


plinabulin

(3Z,6Z)-3-benzylidene-6-[[5-(*tert*-butyl)-1*H*-imidazol-4-yl]methylidene]piperazine-2,5-dione

plinabuline

(3Z,6Z)-3-benzylidène-6-[[5-(*tert*-butyl)-1*H*-imidazol-4-yl]méthylidène]pipérazine-2,5-dione

plinabulina

(3Z,6Z)-3-bencilideno-6-[[5-(*terc*-butil)-1*H*-imidazol-4-il]metilideno]piperazina-2,5-diona $C_{19}H_{20}N_4O_2$ **pridopidinum**

pridopidine



4-[3-(methanesulfonyl)phenyl]-1-propylpiperidine

pridopidine

4-[3-(méthanesulfonyl)phényl]-1-propylpipéridine

pridopidina

4-[3-(metanosulfonyl)fenil]-1-propilpiperidina

**raseglurantum**

raseglurant



2-[2-(3-fluorophenyl)ethynyl]-4,6-dimethylpyridin-3-amine

raségglurant

2-[2-(3-fluorophényl)éthynyl]-4,6-diméthylpyridin-3-amine

raseglurant

2-[2-(3-fluorofenil)etiniil]-4,6-dimetilpiridin-3-amina

**remimazolamum**


remimazolam

methyl 3-((4*S*)-8-bromo-1-methyl-6-(pyridin-2-yl)-4*H*-imidazo[1,2-*a*][1,4]benzodiazepin-4-yl}propanoate

rémimazolam

3-((4*S*)-8-bromo-1-méthyl-6-(pyridin-2-yl)-4*H*-imidazo[1,2-*a*][1,4]benzodiazépin-4-yl}propanoate de méthyle

remimazolam

3-((4*S*)-8-bromo-1-metil-6-(piridin-2-il)-4*H*-imidazo[1,2-*a*][1,4]benzodiazepin-4-il}propanoato de metilo**resminostatum**

resminostat

(2*E*)-3-[1-({4-[(dimethylamino)methyl]phenyl}sulfonyl)-1*H*-pyrrol-3-yl]-*N*-hydroxyprop-2-enamide

resminostat

(2*E*)-3-[1-({4-[(diméthylamino)méthyl]phényl}sulfonyl)-1*H*-pyrrol-3-yl]-*N*-hydroxyprop-2-énamide

resminostat

(2*E*)-3-[1-({4-[(dimetilamino)metil]fenil}sulfonyl)-1*H*-pirrol-3-il]-*N*-hidroxiprop-2-enamida

secukinumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* IL17A (interleukina 17A, IL-17A)], anticuerpo monoclonal de *Homo sapiens*; cadena pesada gamma1 (1-457) [*Homo sapiens* VH (IGHV3-7*01 (92.90%) -(IGHD)-IGHJ2*01) [8.8.20] (1-127) -IGHG1*03 (128-457)], (230-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ2*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; dímero bisdisulfuro-(236-236":239-239")

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFS NYWMNWVRQA PGKGLEWVAA 50
INQDGSEKYY VGSVKGRFTI SRDNAKNSLY LQMNSLRVED TAVYYCVRDY 100
YDILTDDYIH YWYFDLWGRG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA 150
ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTGPS 200
SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV 250
FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK 300
PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTIKAK 350
GQPREPQVYT LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN 400
YKTTTPPVLD SGSFFLYSKL TVDKSRWQQG NVFSCSVME ALHNHYTQKS 450
LSLSPGK 457
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPGT LSLSPGERAT LSCRASQSVS SSYLAWYQQK PGQAPRLLIY 50
GASSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSSTPCTFG 100
QGTRLEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYLSSTL TLISKADYEH KKYACEVTHQ 200
GLSSPVTKSF NRGEK 215
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 154-210 271-331 377-435
22"-96" 154"-210" 271"-331" 377"-435"

Intra-L 23'-89' 135'-195'
23'''-89''' 135'''-195'''

Inter-H-L 230-215' 230"-215"
Inter-H-H 236-236" 239-239"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
307, 307"

selexipagum

selexipag

2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-
N-(methanesulfonyl)acetamide


sélexipag

2-{4-[(5,6-diphénylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-
N-(méthanesulfonyl)acétamide

selexipag

2-{4-[(5,6-difenilpirazin-2-il)(propan-2-il)amino]butoxi}-
N-(metanosulfonyl)acetamida

C₂₆H₃₂N₄O₄S



sotaterceptum

sotatercept

fusion protein for immune applications (FPIA) comprising ACVR2A (activin receptor type 2A, activin receptor type IIA) fragment fused with immunoglobulin G1 Fc fragment, and binding activin, a member of the TGF beta family; ACVR2A, 21-135 precursor fragment (1-115) -threonyl-triglycyl linker (116-119) -gamma1 chain H-CH2-CH3 fragment (120-344) [*Homo sapiens* IGHG1*03 hinge (120-127), CH2, A115>V (128-237), CH3 (238-344)]; (123-123':126-126')-bisdisulfide dimer

sotatercept	protéine de fusion pour applications immunitaires (FPIA) comprenant un fragment d'ACVR2A (récepteur type 2A de l'activine, récepteur type IIA de l'activine) fusionné au fragment Fc de l'immunoglobuline G1, et liant l'activine, un membre de la famille du TGF bêta; fragment précurseur 21-135 de ACVR2A (1-115) -linker thréonil-triglycyl (116-119) -fragment H-CH2-CH3 de chaîne gamma1 (120-344) [<i>Homo sapiens</i> IGHG1*03 charnière (120-127), CH2, A115>V (128-237), CH3 (238-344)]; dimère (123-123':126-126')-bisdisulfure																																																										
sotatercept	<p>proteína de fusión para aplicaciones inmunitarias (FPIA) que comprende un fragmento de ACVR2A (receptor tipo 2A de la activina, receptor tipo IIA de la activina) fusionado al fragmento Fc de la inmunoglobulina G1, y que capta la activina, un miembro de la familia del TGF beta;</p> <p>fragmento precursor 21-135 de ACVR2A (1-115)-conector treonil-triglicil (116-119) -fragmento H-CH2-CH3 de cadena gamma1 (120-344) [<i>Homo sapiens</i> IGHG1*03 bisagra(120-127), CH2, A115>V (128-237), CH3 (238-344)]; dímero (123-123':126-126')-bisdisulfuro</p> <p>C₃₄₄₈H₅₂₆₄N₉₂₀O₁₀₅₈S₄₂</p> <p>Fused chain / chaîne fusionnée / cadena fusionada</p> <table><tr><td>ILGRSETQEC</td><td>LFFNANWEKD</td><td>RTNQTGVEPC</td><td>YGDKDKRRHC</td><td>FATWKNISGS</td><td>50</td></tr><tr><td>IEIVKQGCWL</td><td>DDINCYDRTD</td><td>CVEKKDSPEV</td><td>YFCCCEGNMC</td><td>NEKFSYFPFM</td><td>100</td></tr><tr><td>EVTQPTSNPV</td><td>TPKPPTGGGT</td><td>HTCPCCPAPE</td><td>LLGGPSVFLF</td><td>PPKPKDTLMI</td><td>150</td></tr><tr><td>SRTPEVTCVV</td><td>VDVSHEDPEV</td><td>KFNWYVDGVE</td><td>VHNAKTKPRE</td><td>EQYNSTYRVV</td><td>200</td></tr><tr><td>SVLTVLHQDW</td><td>LNGKEYKCKV</td><td>SNKALPVPPIE</td><td>KTISKAKGQP</td><td>REPQVYTLPP</td><td>250</td></tr><tr><td>SREEMTKNQV</td><td>SLTCLVKGFY</td><td>PSDIAVEWES</td><td>NGQPENNYKT</td><td>TPPVLDSGDS</td><td>300</td></tr><tr><td>FFLYSKLTVD</td><td>KSRWQQGNVF</td><td>SCSVMHEALH</td><td>NHYTQKSLSL</td><td>SPGK</td><td>344</td></tr></table> <p>Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro</p> <table><tr><td>Intra-chain</td><td>10-40</td><td>30-58</td><td>65-84</td><td>71-83</td><td>85-90</td><td>158-218</td><td>264-322</td></tr><tr><td></td><td>10'-40'</td><td>30'-58'</td><td>65'-84'</td><td>71'-83'</td><td>85'-90'</td><td>158'-218'</td><td>264'-322'</td></tr></table> <p>Inter-chains 123-123' 126-126'</p> <p>N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación 23, 46, 194, 23', 46', 194'</p>	ILGRSETQEC	LFFNANWEKD	RTNQTGVEPC	YGDKDKRRHC	FATWKNISGS	50	IEIVKQGCWL	DDINCYDRTD	CVEKKDSPEV	YFCCCEGNMC	NEKFSYFPFM	100	EVTQPTSNPV	TPKPPTGGGT	HTCPCCPAPE	LLGGPSVFLF	PPKPKDTLMI	150	SRTPEVTCVV	VDVSHEDPEV	KFNWYVDGVE	VHNAKTKPRE	EQYNSTYRVV	200	SVLTVLHQDW	LNGKEYKCKV	SNKALPVPPIE	KTISKAKGQP	REPQVYTLPP	250	SREEMTKNQV	SLTCLVKGFY	PSDIAVEWES	NGQPENNYKT	TPPVLDSGDS	300	FFLYSKLTVD	KSRWQQGNVF	SCSVMHEALH	NHYTQKSLSL	SPGK	344	Intra-chain	10-40	30-58	65-84	71-83	85-90	158-218	264-322		10'-40'	30'-58'	65'-84'	71'-83'	85'-90'	158'-218'	264'-322'
ILGRSETQEC	LFFNANWEKD	RTNQTGVEPC	YGDKDKRRHC	FATWKNISGS	50																																																						
IEIVKQGCWL	DDINCYDRTD	CVEKKDSPEV	YFCCCEGNMC	NEKFSYFPFM	100																																																						
EVTQPTSNPV	TPKPPTGGGT	HTCPCCPAPE	LLGGPSVFLF	PPKPKDTLMI	150																																																						
SRTPEVTCVV	VDVSHEDPEV	KFNWYVDGVE	VHNAKTKPRE	EQYNSTYRVV	200																																																						
SVLTVLHQDW	LNGKEYKCKV	SNKALPVPPIE	KTISKAKGQP	REPQVYTLPP	250																																																						
SREEMTKNQV	SLTCLVKGFY	PSDIAVEWES	NGQPENNYKT	TPPVLDSGDS	300																																																						
FFLYSKLTVD	KSRWQQGNVF	SCSVMHEALH	NHYTQKSLSL	SPGK	344																																																						
Intra-chain	10-40	30-58	65-84	71-83	85-90	158-218	264-322																																																				
	10'-40'	30'-58'	65'-84'	71'-83'	85'-90'	158'-218'	264'-322'																																																				
suvizumabum # suvizumab	immunoglobulin G1-kappa, anti-[human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein gp120 third variable loop V3], humanized monoclonal antibody; gamma1 heavy chain (1-448) [humanized VH (<i>Homo sapiens</i> IGHV1-46*01 (77.60%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) - <i>Homo sapiens</i> IGHG1*01 (119-448)], (221-220')-disulfide with kappa light chain (1'-220') [humanized V-KAPPA (<i>Homo sapiens</i> IGKV4-1*01 (77.20%) -IGKJ1*01) [12.3.9] (1'-113') - <i>Homo sapiens</i> IGKC*01 (114'-220')]; (227-227'':230-230'')-bisdisulfide dimer																																																										
suvizumab	immunoglobuline G1-kappa, anti-[troisième boucle variable V3 de la glycoprotéine d'enveloppe gp120 du virus type 1 de l'immunodéficience humaine (VIH-1)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-448) [VH humanisé (<i>Homo sapiens</i> IGHV1-46*01 (77.60%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) - <i>Homo sapiens</i> IGHG1*01 (119-448)], (221-220')-disulfure avec la chaîne légère kappa (1'-220') [V-KAPPA humanisé (<i>Homo sapiens</i> IGKV4-1*01 (77.20%) -IGKJ1*01) [12.3.9] (1'-113') - <i>Homo sapiens</i> IGKC*01 (114'-220')]; dimère (227-227'':230-230'')-bisdisulfure																																																										

suvizumab

inmunoglobulina G1-kappa, anti-[tercer bucle variable V3 de la glicoproteína de la envoltura gp120 del virus tipo 1 de la inmunodeficiencia humana (VIH-1)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-448) [VH humanizado (*Homo sapiens*IGHV1-46*01 (77.60%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01 (119-448)], (221-220')-disulfuro con la cadena ligera kappa (1'-220') [V-KAPPA humanizada (*Homo sapiens* IGKV4-1*01 (77.20%) -IGKJ1*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01 (114'-220')]; dímero bisdisulfuro-(227-227":230-230")

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE VKKPGASVKV SCKASGYTFT NSWIGWFRQA PGQGLEWIGD 50
IYPGGGYTNY NEIFKKGKATM TADTSTNTAY MELSSLRSED TAVYYCSRGI 100
PGYAMDYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSQVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGEVHNNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTFPFVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK 448

Light chain / Chaîne légère / Cadena ligera

DIQMTQRPDS LSASVGDRTV MSCKSSQSLL NSGDQKNYLT WYQKPGQPP 50
KLLIYWASTG ESGVPDRFSG SSGTDFTFTT ISSLPEDIA TYYCNDYSY 100
PWTFGQGTKV EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150
KVQWKVDNAL QSGNSQESVT EQDSKDSYTS LSSITLTSKA DYEKKHVVYAC 200
EVTHQGLSSP VTKSFNRGEC 220

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 21-96 145-201 262-322 368-426
21"-96" 145"-201" 262"-322" 368"-426"
Intra-L 23'-94' 140'-200'
23"-94'" 140'"-200'"
Inter-H-L 221-220' 221"-220"
Inter-H-H 227-227" 230-230"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

298, 298"

tafoxiparinum natricum
tafoxiparin sodium

sodium salt of a low molecular mass heparin that is obtained by periodate oxidative depolymerization of heparin from porcine intestinal mucosa followed alkaline β -elimination and reduction of the products; the majority of the components have a 2-deoxy-6-O-sulfo-2-(sulfoamino)- α -D-glucopyranosyl structure at the non-reducing end and a (hydroxymethyl)allyl 2-deoxy-6-O-sulfo-2-(sulfoamino)- α -D-glucopyranoside structure at the reducing end of their chain; the average molecular mass is approximately 6000 Daltons and 80% of the components ranging between 2000 and 10000 Daltons; the degree of sulfatation is of 2 to 2.5 per disaccharidic unit

tafoxiparine sodique

sel de sodium d'héparine de basse masse moléculaire obtenue par dépolymérisation oxydative, à l'aide de periodate, d'héparine de muqueuse intestinale de porc, suivie d'une β -élimination alcaline puis d'une réduction des produits. La majorité des composants présentent une structure 2-déoxy-6-O-sulfo-2-(sulfoamino)- α -D-glucopyranosyle à l'extrémité non réductrice et une structure 2-déoxy-6-O-sulfo-2-(sulfoamino)- α -D-glucopyranoside de (hydroxyméthyl)allyle à l'extrémité réductrice de leur chaîne; les masses moléculaires relatives des constituants ont une moyenne voisine de 6000 Daltons et celles de 80% des constituants sont comprises entre 2000 et 10000; le degré de sulfatation est compris entre 2 et 2,5 par unité disaccharide

tafoxiparina sódica

sal sódica de la heparina de baja masa molecular obtenida de mucosa intestinal de cerdo por despolimerización oxidativa mediante un proceso controlado en el que se utiliza periodato, seguido de una β -eliminación alcalina y de una reducción de los productos. La mayoría de los componentes presentan la estructura 2-desoxi-6-O-sulfo-2-(sulfoamino)- α -D-glucopiranosilo en el extremo no reductor y la estructura 2-desoxi-6-O-sulfo-2-(sulfoamino)- α -D-glucopiranosido de (hidroximetilo)alilo en el extremo reductor de su cadena ; la masa molecular relativa media es de aproximadamente 6000 daltons y la masa molecular relativa media de 80 % de los componentes está comprendida entre 2000 y 10000, el grado de sulfatación oscila entre 2 y 2,5 por unidad de disacárido

tenifatecanum

tenifatecan


(4S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl (2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydro-2H-chromen-6-yl butanedioate

ténifatécán

butanedioate de (4S)-4,11-diéthyl-4-hydroxy-3,14-dioxo-3,4,12,14-tétrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoléin-9-yle et de (2R)-2,5,7,8-tétraméthyl-2-[(4R,8R)-4,8,12-triméthyltridécy]-3,4-dihydro-2H-chromén-6-yle

tenifatecán

butanodioato de (4S)-4,11-dietil-4-hidroxi-3,14-dioxo-3,4,12,14-tetrahydro-1H-pirano[3',4':6,7]indolizino[1,2-b]quinolin-9-ilo y (2R)-2,5,7,8-tetrametil-2-[(4R,8R)-4,8,12-trimetiltridecil]-3,4-dihidro-2H-cromen-6-ilo

 $C_{55}H_{72}N_2O_9$ **tideglusibum**

tideglusib


4-benzyl-2-(naphthalen-1-yl)-1,2,4-thiadiazolidine-3,5-dione

tidéglusib

4-benzyl-2-(naphtalén-1-yl)-1,2,4-thiadiazolidine-3,5-dione

tideglusib

4-bencil-2-(naftalen-1-il)-1,2,4-tiadiazolidina-3,5-diona

 $C_{19}H_{14}N_2SO_2$ 

tivozanibum

tivozanib


1-{2-chloro-4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-3-(5-methyl-1,2-oxazol-3-yl)urea

tivozanib

1-{2-chloro-4-[(6,7-diméthoxyquinoléin-4-yl)oxy]phényl}-3-(5-méthyl-1,2-oxazol-3-yl)urée

tivozanib

1-{2-cloro-4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-3-(5-metil-1,2-oxazol-3-il)urea

 $C_{22}H_{19}ClN_4O_5$ **tonapofyllinum**


tonapofylline

3-{4-[2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1*H*-purin-8-yl]bicyclo[2.2.2]octan-1-yl}propanoic acid

tonapofylline

acide 3-{4-[2,6-dioxo-1,3-dipropyl-2,3,6,7-tétrahydro-1*H*-purin-8-yl]bicyclo[2.2.2]octan-1-yl}propanoïque

tonapofilina

ácido 3-{4-[2,6-dioxo-1,3-dipropil-2,3,6,7-tetrahidro-1*H*-purin-8-il]biciclo[2.2.2]octan-1-il}propanoico $C_{22}H_{32}N_4O_4$ **topiroxostatam**


topiroxostat

4-[5-(pyridin-4-yl)-1*H*-1,2,4-triazol-3-yl]pyridine-2-carbonitrile

topiroxostat

4-[5-(pyridin-4-yl)-1*H*-1,2,4-triazol-3-yl]pyridine-2-carbonitrile

topiroxostat

4-[5-(piridin-4-il)-1*H*-1,2,4-triazol-3-il]piridina-2-carbonitrilo $C_{13}H_8N_6$ 

tralokinumabum #

tralokinumab

immunoglobulin G4-lambda, anti-[*Homo sapiens* IL13 (interleukin 13, IL-13)], *Homo sapiens* monoclonal antibody;
gamma4 heavy chain (1-449) [*Homo sapiens* VH (IGHV1-18*01 (92.90%) -(IGHD)-IGHJ2*01) [8.8.15] (1-122) -IGHG4*01 (123-449)], (136-213')-disulfide with lambda light chain (1'-214') [*Homo sapiens* V-LAMBDA (IGLV3-21*03 (93.70%) -IGLJ2*01) [6.3.11] (1'-108') -IGLC2*01 (109'-214')]; (228-228'':231-231'')-bisdisulfide dimer

tralokinumab

immunoglobuline G4-lambda, anti-[*Homo sapiens* IL13 (interleukine 13, IL-13)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma4 (1-449) [*Homo sapiens* VH (IGHV1-18*01 (92.90%) -(IGHD)-IGHJ2*01) [8.8.15] (1-122) -IGHG4*01(123-449)], (136-213')-disulfure avec la chaîne légère lambda (1'-214') [*Homo sapiens* V-LAMBDA (IGLV3-21*03 (93.70%) -IGLJ2*01) [6.3.11] (1'-108') -IGLC2*01 (109'-214')]; dimère (228-228'':231-231'')-bisdisulfure

tralokinumab

inmunoglobulina G4-lambda, anti-[IL13 (interleukina 13, IL-13) de *Homo sapiens*], anticuerpo monoclonal de *Homo sapiens*;
cadena pesada gamma4 (1-449) [*Homo sapiens* VH (IGHV1-18*01 (92.90%) -(IGHD)-IGHJ2*01) [8.8.15] (1-122) -IGHG4*01(123-449)], (136-213')-disulfuro con la cadena ligera lambda (1'-214') [*Homo sapiens* V-LAMBDA (IGLV3-21*03 (93.70%) -IGLJ2*01) [6.3.11] (1'-108') -IGLC2*01 (109'-214')]; dímero (228-228'':231-231'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYTFT NYGLSWVRQA PGQGLEWMGW 50
ISANNQDTNY GQEFQGRVTM TTDSTSTSTAY MELRSLRSDD TAVYYCARD 100
SSSWARWFFD LWGRGTLVTV SSASTKGPSV FPLAPCSRST SESTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTPSSSLGT 200
KTYTCNVNDR PSNTKVDKRV ESKYGPSPCP CPAEFLGGP SVFLFPKPK 250
DTLMISRTPV VTCVVVDVQS EDPEVQFNWY VDGVEVHNAK TKPREEQFNS 300
TYRVVSVLTV LQDQWLNKGE YKCKVSNKGL PSSIEKTISK AKGQPREPQV 350
YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNVKTTTPVL 400
DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK 449
```

Light chain / Chaîne légère / Cadena ligera

```
SYVLTQPPSV SVAPGKTARI TCGGNIIGSK LVHWYQKPG QAPVLYIYDD 50
GDRPSGIPER FSGSNSGNTA TLTISRVEAG DEADYYCQVW DTGSDPVPVFG 100
GGTKLTVLGQ PKAAPSVTLF PPSSEELQAN KATLVCLISD FYPGAVTVAV 150
KADSSPVKAG VETTTPSKQS NNKYAASSYL SLTPEQWKSH RSYSCQVTHE 200
GSTVEKTVAP TECS 214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H 22-96 149-205 263-323 369-427
          22"-96" 149"-205" 263"-323" 369"-427"
Intra-L 22'-87' 136'-195'
          22"'-87'" 136"'-195'"
Inter-H-L 136-213' 136"-213"
Inter-H-H 228-228" 231-231"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

299, 299"

varlitinibum

varlitinib


N^4 -{3-chloro-4-[(1,3-thiazol-2-yl)methoxy]phenyl}- N^6 -[(4*R*)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine

varlitinib

N^4 -{3-chloro-4-[(1,3-thiazol-2-yl)méthoxy]phényl}- N^6 -[(4*R*)-4-méthyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine

varlitinib

N^4 -{3-cloro-4-[(1,3-tiazol-2-il)metoxi]fenil}- N^6 -[(4*R*)-4-metil-4,5-dihidro-1,3-oxazol-2-il]quinazolina-4,6-diamina

$C_{22}H_{19}ClN_6O_2S$ **veliparibum**


veliparib

2-[(2*R*)-2-méthylpyrrolidin-2-yl]-1*H*-benzimidazole-4-carboxamide

véliparib

2-[(2*R*)-2-méthylpyrrolidin-2-yl]-1*H*-benzimidazole-4-carboxamide

veliparib

2-[(2*R*)-2-metilpirrolidin-2-il]-1*H*-benzoimidazol-4-carboxamida $C_{13}H_{16}N_4O$ **verucerfontum**


verucerfont

3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-*N*-[(1*S*)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]pyrazolo[1,5-*a*]pyrimidin-7-amine

vérucerfont

3-(4-méthoxy-2-méthylphényl)-2,5-diméthyl-*N*-[(1*S*)-1-(3-méthyl-1,2,4-oxadiazol-5-yl)propyl]pyrazolo[1,5-*a*]pyrimidin-7-amine

verucerfont

2,5-dimetil-3-(2-metilfenil-4-metoksi)-*N*-[(1*S*)-1-(3-metil-1,2,4-oxadiazol-5-il)propil]pirazolo[1,5-*a*]pirimidin-7-amina $C_{22}H_{26}N_6O_2$ **volasertibum**

volasertib


N-{*trans*-4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl}-4-[[*(7R)*]-7-éthyl-5-méthyl-6-oxo-8-(propan-2-yl)-5,6,7,8-tétrahydroptéridin-2-yl]amino-3-méthoxybenzamide

volasertib

N-{*trans*-4-[4-(cyclopropylméthyl)pipérazin-1-yl]cyclohexyl}-4-[[*(7R)*]-7-éthyl-5-méthyl-6-oxo-8-(propan-2-yl)-5,6,7,8-tétrahydroptéridin-2-yl]amino-3-méthoxybenzamide

volasertib

N-{*trans*-4-[4-(ciclopropilmetil)piperazin-1-il]ciclohexil}-4-[[*(7R)*]-7-etil-5-metil-6-oxo-8-(propan-2-il)-5,6,7,8-tetrahidropteridin-2-il]amino-3-metoxibenzamida

C₃₄H₅₀N₈O₃**vonicogum alfa #**

vonicog alfa

[618-threonine,709-aspartic acid]von Willebrand factor *Homo sapiens* (1381A>T,1472H>D variant)

vonicog alfa

[618-thréonine,709-acide aspartique]facteur de von Willebrand *Homo sapiens* (variant 1381A>T,1472H>D)

vonicog alfa

[618-treonina,709-ácido aspático]factor de von Willebrand *Homo sapiens* (variante 1381A>T,1472H>D)C₉₇₁₂H₁₅₃₇₃N₂₇₃₇O₃₀₃₂S₂₁₀

SLSCRPFPMVK LVCPADNLRA EGGLETKTCQ NYDLECMSMG CVSGCLCPPG 50
MVRHENRCVA LERCPCFHQG KEYAPGETVK IGCNTCVCRD RKWNCTDHVC 100
DATCSTIGMA HYLTFDGLKY LFPGECQYVL VQDYCGSNPG TFRILVGNKG 150
CSHPSVKCKK RVTILVEGGE IELFDGEVNV KRPMKDETHF EVVESGRYII 200
LLLGKALSVV WDRHLSISVV LKQTYQEKVC GLCGNFDGIQ NNDLTSSNLQ 250
VEEDPVDFGN SWKVSSQCAD TRKVPLDSSP ATCHNNIMQ TMVDSSCRIL 300
TSDVFDQCNK LVDPEPYLDV CIYDTCSCES IGDCACFCDT IAAAHVCAQ 350
HGKVVWRTA TLCQSCSEER NLRENGYECE WRYNSCAPAC QVTCQHPEPL 400
ACPVQCVEGC HAHCPPGKIL DELLQTCVDP EDCPVCEVAG RRFASGKVT 450
LNPSDPEHCQ ICHCDVNLIT CEACQEPGGL VVPPTDAPVS PTTLYVEDIS 500
EPPLHDFYCS RLLEDLVFLD GSSRLSEAEF EVLKAFVVDV MERLRISQKW 550
VRVAVVEYHD GSHAYIGLKD RKRPELRRRI ASQVKYAGSQ VASTSEVLKY 600
TLFQIFSKID RPEASRITLL LMASQEPQRM SRNPFVRVVG LKKKKVIVIP 650
VGIGPHANLK QIRLIEKQAP ENKAFVLSSV DELEQQRDEI VSYLCDLAPE 700
APPPTLPDM AQVTGPGLL GVSTLGPKNR SMVLDVAFVL EGSDKIGEAD 750
FNRSKEFME VQRMDDVGD SIHVTVLQYS YMVTVVEYFES EAQSKGDILQ 800
RVREIRYQGG NRTNTGLALR YLSDHSFLVS QGDREQAPNL VYMTGNPAS 850
DEIKRLPGDI QVVPIGVGPN ANVQELERIG WPNAPILIQD FETLPREAPD 900
LVLQRCCSGE GLQIPTLSPL PDCSQPLDVI LLLDGSSSFP ASYFDEMKSF 950
AKAFISKANI GPRLTQVSVL QYGSITIDV PWNVVPKAKH LLSLVDMVQR 1000
EGGPSQIGDA LGFAVRYLTS EMHGARPAS KAVVILVTDV SVDSVDAAAD 1050
AARSNRVTVF PIGIGDRYDA AQLRILAGPA GDSNVVKLQR IEDLPTMVT 1100
GNSFLHKLCS GFVRICMDED GNEKRPDGVW TLPDQCHTVT CQPDGQTLK 1150
SHRVNCDRGL RPSCPNQSP VKVEETCGCR WTCPCVCTGS STRHIVTFDG 1200
QNFKLTGSCS YVLFQNKED LEVILHNGAC SPGARQGCMM SIEVKHSALS 1250
VELHSDMEVT VNGRLVSPY VGGNMEVNVY GAIMHEVRFN HLGHIFFTF 1300
QNNFQLQLS PKTFASKTYG LCGICDENG NDMLRDGTV TTDWKTIVQE 1350
WTVQRPQGT QPILEEQCLV PDSSHCQVLL LPLFAECHKV LAPATFYAIC 1400
QQDSCHQEQV CEVIASYAHL CRTNGVCVDW RTPDFCAMS PPSLVYNHCE 1450
HGCPRHCDGN VSSCGDHPSE GCFPPDPKVM LEGSCVPPEA CTQCIGEDGV 1500
QHQLFLEAWP DHQPCQICTC LSGRKNVCTT QPCPTAKAPT CGLCEVARLR 1550
QNADQCCPEY ECVCDEPVSCD LPPVPHCERG LQPTLTNPGE CRPNFTCACR 1600
KEECKRVSP SCPPHRLPTL RKTQCCDEYE CACNCNVSTV SCPLGYLAST 1650
ATNDGCTTT TCLPDKVCVH RSTIYPVGQF WEEGCDVCTC TDMDAVMGL 1700
RVAQCSQKPC EDSRSGFTY VLHEGECGR CLPSACEVVT GSFRGDSQSS 1750
WKSVGSGWAS PENPCLINEC VRVKEEVFIQ QRNVSCPQLE VPCFSGFQL 1800
SCKTSACCPS CRCERMEACM LNTGTVIGPK TVMIDVCTTC RCMVQGVVIS 1850
GFKLECRKTT CNPCPLGYKE ENNTGECGR CLPTACTIQL RGGQIMTLKR 1900
DETLQDGCDD HFCKVNERGE YFWEKRVTCG PPFDEHKCLA EGGKIMKIP 1950
TCCDTCEEPE CNDITARLQY VKVGSKSEV EVDIHYCQGK CASKAMYSID 2000
INDVQDQCSC CSPTTRTEPMQ VALHCTNGSV VYHEVLNAME CKCSPRKCSK 2050

yttrium (⁹⁰Y) clivatuzumabum tetraxetanum #
yttrium (⁹⁰Y) clivatuzumab tetraxetan

immunoglobulin G1-kappa, anti-[*Homo sapiens* MUC1 (mucin 1, polymorphic epithelial mucin, PEM, CD227)], humanized monoclonal antibody, yttrium (⁹⁰Y) radiolabelled tetraxetan conjugate; gamma1 heavy chain (1-449) [humanized VH (*Homo sapiens*IGHV1-2*02 (79.60%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens*IGHG1*03 (120-449)], (222-215')-disulfide with kappa light chain (1'-215') [humanized V-KAPPA (*Homo sapiens*IGKV1-13*02 (78.90%) -IGKJ2*01) [7.3.9] (1'-108') -*Homo sapiens*IGKC*01 (109'-215')]; (228-228":231-231")-bisdisulfide dimer; yttrium (⁹⁰Y) radiolabelled tetraxetan (DOTA) conjugate

yttrium (⁹⁰Y) clivatuzumab tétraxétan

immunoglobuline G1-kappa, anti-[*Homo sapiens* MUC1 (mucine 1, mucine épithéliale polymorphe, PEM, CD227)], anticorps monoclonal humanisé, conjugué au tétraxétan et radiomarcué à l'yttrium (⁹⁰Y); chaîne lourde gamma1 (1-449) [VH humanisé (*Homo sapiens*IGHV1-2*02 (79.60%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens*IGHG1*03 (120-449)], (222-215')-disulfure avec la chaîne légère kappa (1'-215') [V-KAPPA humanisé (*Homo sapiens*IGKV1-13*02 (78.90%) -IGKJ2*01) [7.3.9] (1'-108') -*Homo sapiens*IGKC*01 (109'-215')]; dimère (228-228":231-231")-bisdisulfure; conjugué au tétraxétan (DOTA) et radiomarcué à l'yttrium (⁹⁰Y)

yttrio (⁹⁰Y) clivatuzumab tetraxetán

inmunoglobulina G1-kappa, anti-[*Homo sapiens* MUC1 (mucina 1, mucina epitelial polimórfica, PEM, CD227)], anticuerpo monoclonal humanizado, conjugado al tetraxetano y radiomarcado con yttrio (⁹⁰Y); cadena pesada gamma1 (1-449) [VH humanizada (*Homo sapiens*IGHV1-2*02 (79.60%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens*IGHG1*03 (120-449)], (222-215')-disulfuro con la cadena ligera kappa (1'-215') [V-KAPPA humanizada (*Homo sapiens*IGKV1-13*02 (78.90%) -IGKJ2*01) [7.3.9] (1'-108') -*Homo sapiens*IGKC*01 (109'-215')]; dimero (228-228":231-231")-bisdisulfuro; conjugada al tetraxetano (DOTA) y radiomarcado con yttrio (⁹⁰Y)

Heavy chain / Chaîne lourde / Cadena pesada

QVQLQQSGAE VKKPGASVKV SCEASGYTFP SYVLHWVKQA PGQGLEWIGY 50
 INPYNDGTQY NEKFKGKATL TRDTSINTAY MELSRLRSDD TAVYYCARGF 100
 GGSYGFAYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
 YFPEPVTVSW NSGALTSGVH TFPVAVLQSSG LYSLSVVTV PSSSLGTQTY 200
 ICNVNHPKPSN TKVDKRVPEK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
 DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
 TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
 YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTTPVL 400
 DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK 449

Light chain / Chaîne légère / Cadena ligera


DIQLTQSPSS LSASVGDRVT MTCASASSVS SSYLYWYQOK PGKAPKLWIY 50
 STSNLASGVP ARFSGSGSGT DFTLTISLQ PEDSASYFCH QWNRYPTYFG 100
 GGTRLEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
 VDNALQSGNS QESVTEQDSK DSTYLSSTL TLSKADYEKH KUYACEVTHQ 200
 GLSSPVTKSF NRGEC 215

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 146-202 263-323 369-427
 22"-96" 146"-202" 263"-323" 369"-427"
 Intra-L 23'-89' 135'-195'
 23"'-89'" 135"'-195'"
 Inter-H-L 222-215' 222"-215"
 Inter-H-H 228-228" 231-231"

Modified residues / Résidus modifiés / Residuos modificados

Substitution ratio of 2 to 5 lysyl (K)
 out of the 90 of the antibody molecule
 Λ^6 -(^{90}Y -yttrium tetraxetan)-L-lysyl



N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
 299, 299"

zoleprodololum

zoleprodolol


(±)-1-(2-[(3-methoxy-1,2,4-oxadiazol-5-yl)methoxy]phenoxy)-3-[(*tert*-butylamino)]propan-2-ol

zoléprodolol

(±)-1-(2-[(3-methoxy-1,2,4-oxadiazol-5-yl)methoxy]phenoxy)-3-[(*tert*-butylamino)]propan-2-ol

zoleprodolol

(±)-1-(2-[(3-metoxi-1,2,4-oxadiazol-5-il)metoxi]fenoxi)-3-[(*terc*-butilamino)]propan-2-ol

C₁₇H₂₅N₃O₅

todo-P-ambo-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-timidina

p. 46 **bixalomerum**

bixalomer
bixalomère
bixalómero

replace the chemical name by the following
remplacer le nom chimique par le suivant
sustitúyase el nombre químico por el siguiente

cross linked polymer made of *N,N,N',N'*-tetrakis(3-aminopropyl)butane-1,4-diamine *N* substituted by bivalent substituent groups 2-hydroxypropane-1,3-diyl and 1-(hydroxymethyl)ethylene ($x=20, 45 \leq y \leq 50$)

N,N,N',N'-tétrakis(3-aminopropyl)butane-1,4-diamine *N* substituée par les groupes substituants divalents 2-hydroxypropane-1,3-diyle et 1-(hydroxyméthyl)éthane-1,2-diyle pour former un polymère réticulé ($x=20, 45 \leq y \leq 50$)

N,N,N',N'-tétrakis(3-aminopropil)butano-1,4-diamina *N* sustituida por los grupos sustituyentes divalentes 2-hidroxipropano-1,3-diilo y 1-(hidroximetil)etileno para formar un polímero reticulado ($x=20, 45 \leq y \leq 50$)

p. 63	delete/supprimer/suprimáse isopropylis turofexoras isopropyl de turofexorate	insert/insérer/insértese turofexoras isopropylis turofexorate d'isopropyle
-------	---	---

Electronic structure available on Mednet: <http://mednet.who.int/>
Structure électronique disponible sur Mednet: <http://mednet.who.int/>
Estructura electrónica disponible en Mednet: <http://mednet.who.int/>

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.